ArticleACS omega2024
Enhancing
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Deep generative models for 3D structure-based drug design and molecular optimisation: a comprehensive survey.Journal of computer-aided molecular design · 2026Review
- Data-driven design and screening of novelRSC advances · 2026Article
- Article
- Disentangled autoencoding equivariant diffusion model for controlled generation of 3D molecules.Nature communications · 2026Article
- VeGA: A Versatile Generative Architecture for Bioactive Molecules across Multiple Therapeutic Targets.Journal of chemical information and modeling · 2025Article
- Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development.MedComm · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery is a costly and time-consuming process, necessitating innovative strategies to enhance efficiency across different stages, from initial hit identification to final market approval. Recent advancement in deep learning (DL), particularly in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.